Philip Morris Presents Scientific Evidence To FDA's Tobacco Products Scientific Advisory Committee As Part Of FDA's Process For MRTP Designation For ZYN Nicotine Pouch Products

In January 2025, ZYN became the first nicotine pouch product authorized for marketing by the FDA

Experts from Philip Morris International (PMI) (NYSE:PM) yesterday presented scientific evidence to the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) as part of the FDA's process for a Modified Risk Tobacco Product (MRTP) designation for their ZYN nicotine pouch products. This designation would allow PMI's U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that switching completely to ZYN reduces their risk of many smoking-related diseases and we look forward to a decision by FDA.